{"id":27295,"date":"2024-05-02T09:38:09","date_gmt":"2024-05-02T07:38:09","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=27295"},"modified":"2024-05-29T15:53:19","modified_gmt":"2024-05-29T13:53:19","slug":"lipum-genomfor-foretradesemission-och-ingar-ramavtal-om-lakemedelstillverkning","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/lipum-genomfor-foretradesemission-och-ingar-ramavtal-om-lakemedelstillverkning\/","title":{"rendered":"Lipum genomf\u00f6r f\u00f6retr\u00e4desemission och ing\u00e5r ramavtal om l\u00e4kemedelstillverkning"},"content":{"rendered":"<p class=\"preamble\">Lipum AB (publ) har genomf\u00f6rt en f\u00f6retr\u00e4desemission om cirka 80 MSEK.<\/p>\n<p>Nettolikviden fr\u00e5n f\u00f6retr\u00e4desemissionen ska huvudsakligen anv\u00e4ndas f\u00f6r fullf\u00f6ljandet av den p\u00e5g\u00e5ende kliniska fas 1-studien av l\u00e4kemedelskandidaten SOL-116 samt f\u00f6r nyproduktion av SOL-116 inf\u00f6r kliniska fas 2-studier enligt ett ramavtal f\u00f6r bl.a. forskning, utveckling och tillverkning av SOL-116 som pr\u00f6vningsl\u00e4kemedel som Lipum har ing\u00e5tt med NorthX Biologics AB.<\/p>\n<p>Lipum \u00e4r ett biofarmaceutiskt bolag i klinisk fas specialiserat p\u00e5 uppt\u00e4ckt och utveckling av ny behandling f\u00f6r kroniska inflammatoriska sjukdomar. L\u00e4kemedelskandidaten SOL-116 \u00e4r en humaniserad antikropp som ska ge s\u00e4krare och effektivare behandling genom att blockera en tidigare f\u00f6rbisedd m\u00e5lmolekyl (BSSL) i immunf\u00f6rsvaret. Lipums aktier \u00e4r noterade p\u00e5 Nasdaq First North Growth Market (LIPUM).<\/p>\n<p>Lipum r\u00e5dgavs av Mannheimer Swartling i samband med f\u00f6retr\u00e4desemissionen och ing\u00e5endet av ramavtalet.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipum AB (publ) har genomf\u00f6rt en f\u00f6retr\u00e4desemission om cirka 80 MSEK. Nettolikviden fr\u00e5n f\u00f6retr\u00e4desemissionen ska huvudsakligen anv\u00e4ndas f\u00f6r fullf\u00f6ljandet av den p\u00e5g\u00e5ende kliniska fas 1-studien\u2026<\/p>\n","protected":false},"author":16,"featured_media":27296,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-27295","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-healthcare-and-life-sciences","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":27295,"en":27300},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27295"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=27295"}],"version-history":[{"count":3,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27295\/revisions"}],"predecessor-version":[{"id":27302,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/27295\/revisions\/27302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/27296"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=27295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=27295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=27295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}